vimarsana.com
Home
Live Updates
Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC : vimarsana.com
Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC
Key opinion leaders review the use of antibody-drug conjugates (ADCs) in treating HR+/HER2- metastatic breast cancer, and how they counsel patients before starting them on therapy with an ADC.
Related Keywords
Elizabeth Diaz ,
,
Virginia Kaklamani ,
Breast Cancer ,
Hr Her2 Metastatic Breast Cancer ,
Mbc ,
Hr Her2 Mbc ,
Metastatic Breast Cancer ,
Clinical Practice ,
Ut Health San Antonio ,
Adcs ,
Endocrine Resistance ,
Premenopausal ,
Postmenopausal ,
Metastatic Breast Cancer Chemotherapy ,
Hr Her2 Metastatic Breast Cancer Treatments ,
vimarsana.com © 2020. All Rights Reserved.